Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.

Hong DS, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL.

Clin Cancer Res. 2019 Apr 15;25(8):2403-2413. doi: 10.1158/1078-0432.CCR-18-1341. Epub 2018 Nov 13.

PMID:
30425090
2.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

3.

Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.

Trivedi A, Stienen S, Zhu M, Li H, Yuraszeck T, Gibbs J, Heath T, Loberg R, Kasichayanula S.

Clin Transl Sci. 2017 May;10(3):147-162. doi: 10.1111/cts.12459. Epub 2017 Mar 15. Review. No abstract available.

4.

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.

Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F.

Cancer. 2017 May 15;123(6):1061-1070. doi: 10.1002/cncr.30437. Epub 2016 Dec 7.

5.

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, Willems SM, Lolkema MP.

PLoS One. 2016 Feb 26;11(2):e0149405. doi: 10.1371/journal.pone.0149405. eCollection 2016.

6.

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.

Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P.

Oncotarget. 2015 Jul 30;6(21):18693-706.

7.

Measuring postural sway in sitting: a new segmental approach.

Curtis DJ, Hansen L, Luun M, Løberg R, Woollacott M, Saavedra S, Sonne-Holm S, Berggreen S, Bencke J.

J Mot Behav. 2015;47(5):427-35. doi: 10.1080/00222895.2014.1003782. Epub 2015 Mar 2.

PMID:
25730683
8.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G, Ikeda M, Melichar B, Nemecek R, Ohkawa S, Świeboda-Sadlej A, Tjulandin SA, Van Cutsem E, Loberg R, Haddad V, Gansert JL, Bach BA, Carrato A.

Ann Oncol. 2015 May;26(5):921-7. doi: 10.1093/annonc/mdv027. Epub 2015 Jan 21.

9.

AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.

Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, Zoog S, Kendall R, Radinsky R, Loberg R, Friberg G, Payton M.

J Transl Med. 2014 Nov 4;12:307. doi: 10.1186/s12967-014-0307-x.

10.

Myocardial mechanics in noncontiguous HCM.

Agarwal A, Khandheria BK, Paterick TE, Bloomgarden D, Loberg R, Bush M, Tajik AJ.

JACC Cardiovasc Imaging. 2013 Nov;6(11):1216-8. doi: 10.1016/j.jcmg.2013.04.016. No abstract available.

11.

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.

Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R.

Mol Cancer Ther. 2013 Nov;12(11):2356-66. doi: 10.1158/1535-7163.MCT-12-1178. Epub 2013 Aug 29.

12.

Aortopathies: etiologies, genetics, differential diagnosis, prognosis and management.

Paterick TE, Humphries JA, Ammar KA, Jan MF, Loberg R, Bush M, Khandheria BK, Tajik AJ.

Am J Med. 2013 Aug;126(8):670-8. doi: 10.1016/j.amjmed.2013.01.029. Epub 2013 Jun 22. Review.

PMID:
23800581
13.

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP.

Ann Oncol. 2013 Jul;24(7):1777-85. doi: 10.1093/annonc/mdt057. Epub 2013 Mar 19.

14.

Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.

Schenkel LB, Huang X, Cheng A, Deak HL, Doherty E, Emkey R, Gu Y, Gunaydin H, Kim JL, Lee J, Loberg R, Olivieri P, Pistillo J, Tang J, Wan Q, Wang HL, Wang SW, Wells MC, Wu B, Yu V, Liu L, Geuns-Meyer S.

J Med Chem. 2011 Dec 22;54(24):8440-50. doi: 10.1021/jm200911r. Epub 2011 Nov 16.

PMID:
22087750
15.

Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.

Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS.

J Clin Invest. 2011 Apr;121(4):1298-312. doi: 10.1172/JCI43414. Epub 2011 Mar 23.

16.

GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche.

Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS.

Neoplasia. 2010 Feb;12(2):116-27.

17.

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK.

Cancer Res. 2009 Feb 15;69(4):1685-92. doi: 10.1158/0008-5472.CAN-08-2164. Epub 2009 Jan 27.

18.

A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.

Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC 3rd.

Am J Physiol Cell Physiol. 2008 Sep;295(3):C836-43. doi: 10.1152/ajpcell.00554.2007. Epub 2008 Jul 23.

19.

CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac.

van Golen KL, Ying C, Sequeira L, Dubyk CW, Reisenberger T, Chinnaiyan AM, Pienta KJ, Loberg RD.

J Cell Biochem. 2008 Aug 1;104(5):1587-97. doi: 10.1002/jcb.21652.

20.

Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer.

Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS.

J Cell Biochem. 2008 Oct 1;105(2):370-80. doi: 10.1002/jcb.21835.

21.

An in vivo mouse model for human prostate cancer metastasis.

Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, McCauley LK, Loberg RD, Pienta KJ, Taichman RS.

Neoplasia. 2008 Apr;10(4):371-80.

23.

The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer.

Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS.

J Biol Chem. 2008 Feb 15;283(7):4283-94. Epub 2007 Dec 5.

24.

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ.

Cancer Res. 2007 Oct 1;67(19):9417-24.

25.

The evolving biology and treatment of prostate cancer.

Taichman RS, Loberg RD, Mehra R, Pienta KJ.

J Clin Invest. 2007 Sep;117(9):2351-61.

26.

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ.

Neoplasia. 2007 Jul;9(7):556-62.

27.

The lethal phenotype of cancer: the molecular basis of death due to malignancy.

Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ.

CA Cancer J Clin. 2007 Jul-Aug;57(4):225-41. Review. Erratum in: CA Cancer J Clin. 2007 Nov-Dec;57(6):380.

28.
29.

PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.

Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ.

J Cell Biochem. 2007 Aug 1;101(5):1292-300.

30.

Can we target the chemokine network for cancer therapeutics?

Giles R, Loberg RD.

Curr Cancer Drug Targets. 2006 Dec;6(8):659-70. Review.

PMID:
17168671
31.

The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.

Wang J, Loberg R, Taichman RS.

Cancer Metastasis Rev. 2006 Dec;25(4):573-87. Review.

PMID:
17165132
32.

CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases.

Craig MJ, Loberg RD.

Cancer Metastasis Rev. 2006 Dec;25(4):611-9. Review.

PMID:
17160712
33.

CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ.

Neoplasia. 2006 Jul;8(7):578-86.

34.

Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ.

Neoplasia. 2006 Jan;8(1):69-78.

35.

Development of the VCaP androgen-independent model of prostate cancer.

Loberg RD, St John LN, Day LL, Neeley CK, Pienta KJ.

Urol Oncol. 2006 Mar-Apr;24(2):161-8.

36.

Analysis of membrane-bound complement regulatory proteins in prostate cancer.

Loberg RD, Wojno KJ, Day LL, Pienta KJ.

Urology. 2005 Dec;66(6):1321-6.

PMID:
16360477
37.

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

Loberg RD, Logothetis CJ, Keller ET, Pienta KJ.

J Clin Oncol. 2005 Nov 10;23(32):8232-41. Review.

PMID:
16278478
38.

PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.

Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA, Pienta KJ.

J Cell Biochem. 2005 Oct 15;96(3):641-52.

39.

The "emigration, migration, and immigration"of prostate cancer.

Pienta KJ, Loberg R.

Clin Prostate Cancer. 2005 Jun;4(1):24-30. Review.

PMID:
15992458
40.
41.

GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta.

Park JL, Loberg RD, Duquaine D, Zhang H, Deo BK, Ardanaz N, Coyle J, Atkins KB, Schin M, Charron MJ, Kumagai AK, Pagano PJ, Brosius FC 3rd.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1596-602. Epub 2005 May 12.

PMID:
15890973
42.

Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology.

Loberg RD, Neeley CK, Adam-Day LL, Fridman Y, St John LN, Nixdorf S, Jackson P, Kalikin LM, Pienta KJ.

Int J Oncol. 2005 Jun;26(6):1699-705.

PMID:
15870888
43.

Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.

Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ.

Urology. 2005 Mar;65(3):616-21.

PMID:
15780403
44.

Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.

Nixdorf S, Grimm MO, Loberg R, Marreiros A, Russell PJ, Pienta KJ, Jackson P.

Cancer Lett. 2004 Nov 25;215(2):209-20.

PMID:
15488640
45.

Detection and isolation of circulating tumor cells in urologic cancers: a review.

Loberg RD, Fridman Y, Pienta BA, Keller ET, McCauley LK, Taichman RS, Pienta KJ.

Neoplasia. 2004 Jul-Aug;6(4):302-9. Review.

46.

Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension.

Wehrwein EA, Northcott CA, Loberg RD, Watts SW.

J Pharmacol Exp Ther. 2004 Jun;309(3):1011-9. Epub 2004 Feb 24.

PMID:
14982964
47.

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ.

Urology. 2003 Dec 29;62 Suppl 1:128-33. Review.

PMID:
14747050
48.

PI3-kinase-induced hyperreactivity in DOCA-salt hypertension is independent of GSK-3 activity.

Loberg RD, Northcott CA, Watts SW, Brosius FC 3rd.

Hypertension. 2003 Apr;41(4):898-902. Epub 2003 Mar 10.

PMID:
12629035
49.
50.

Supplemental Content

Loading ...
Support Center